ZHU:CA:TSX-BMO Equal Weight US Health Care (CAD)

COMMON STOCK | |

Last Closing

CAD 41.6

Change

-0.46 (-1.09)%

Market Cap

CAD 0.05B

Volume

700.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-26 )

Largest Industry Peers for

Symbol Name Price(Change) Market Cap
TD-PFB:CA Toronto Dominion Bank Pref B

-0.13 (-0.53%)

CAD 192.15B
TD-PFD:CA Toronto Dominion Bank Pref D

-0.01 (-0.04%)

CAD 161.10B
TD-PFI:CA Toronto-Dominion Bank Pref Ser..

-0.06 (-0.24%)

CAD 153.48B
TD-PFL:CA Toronto-Dominion Bank Pref Ser..

N/A

CAD 141.08B
TD-PFM:CA Toronto-Dominion Bank Pref Ser..

-0.02 (-0.08%)

CAD 140.97B
ENB-PFA:CA Enbridge Inc Pref 9

-0.05 (-0.27%)

CAD 112.66B
ENB-PFV:CA Enbridge Inc Pref 5

N/A

CAD 111.29B
ENB-PFC:CA Enbridge Inc Pref 11

-0.08 (-0.45%)

CAD 107.08B
ENB-PFG:CA Enbridge Inc Pref 15

-0.01 (-0.06%)

CAD 101.09B
ENB-PFU:CA Enbridge Inc Pref L

+0.25 (+1.21%)

CAD 80.98B

ETFs Containing ZHU:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification () Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 1.59% N/A N/A 40% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.59% N/A N/A 36% F
Trailing 12 Months  
Capital Gain -3.66% N/A N/A 30% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.66% N/A N/A 24% F
Trailing 5 Years  
Capital Gain 43.60% N/A N/A 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 43.60% N/A N/A 65% D
Average Annual (5 Year Horizon)  
Capital Gain 7.52% N/A N/A 69% C-
Dividend Return 7.52% N/A N/A 63% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 13.29% N/A N/A 60% D-
Risk Adjusted Return 56.59% N/A N/A 81% B-
Market Capitalization 0.05B N/A N/A 27% F

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike